Pfizer Inc. (NYSE:PFE) Shares Acquired by Lakeview Capital Partners LLC

Lakeview Capital Partners LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,428 shares of the biopharmaceutical company’s stock after acquiring an additional 1,320 shares during the period. Lakeview Capital Partners LLC’s holdings in Pfizer were worth $860,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. BlackRock Inc. increased its position in shares of Pfizer by 0.8% during the second quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock valued at $13,980,372,000 after acquiring an additional 3,464,207 shares during the last quarter. State Street Corp boosted its stake in shares of Pfizer by 0.3% in the first quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock valued at $9,551,162,000 after purchasing an additional 830,299 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Pfizer by 1.8% in the second quarter. Bank of New York Mellon Corp now owns 57,111,863 shares of the biopharmaceutical company’s stock valued at $1,867,559,000 after purchasing an additional 1,024,264 shares during the period. Sanders Capital LLC boosted its stake in shares of Pfizer by 5.0% in the second quarter. Sanders Capital LLC now owns 28,282,011 shares of the biopharmaceutical company’s stock valued at $1,046,595,000 after purchasing an additional 1,349,012 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Pfizer by 1.4% in the second quarter. Swiss National Bank now owns 23,365,691 shares of the biopharmaceutical company’s stock valued at $764,058,000 after purchasing an additional 327,400 shares during the period. Institutional investors and hedge funds own 69.08% of the company’s stock.

PFE stock traded up $1.40 during midday trading on Friday, reaching $37.95. 40,790,772 shares of the company were exchanged, compared to its average volume of 28,495,957. The stock’s 50-day simple moving average is $36.59 and its 200 day simple moving average is $36.32. The company has a market cap of $210.88 billion, a price-to-earnings ratio of 15.06, a price-to-earnings-growth ratio of 2.91 and a beta of 0.67. Pfizer Inc. has a 1-year low of $27.88 and a 1-year high of $40.97. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.14. The business had revenue of $11.80 billion for the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The company’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.80 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.89 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be issued a $0.38 dividend. The ex-dividend date of this dividend is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. Pfizer’s payout ratio is 51.53%.

PFE has been the subject of several recent research reports. ValuEngine lowered shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. Royal Bank of Canada set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday. Atlantic Securities downgraded shares of Pfizer from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $44.00 to $39.00 in a research note on Monday, October 12th. Morgan Stanley lifted their price target on shares of Pfizer from $36.00 to $42.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Finally, Mizuho reiterated a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research note on Tuesday, September 15th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $39.64.

In other Pfizer news, Director Ronald E. Blaylock bought 13,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were acquired at an average cost of $38.55 per share, with a total value of $501,150.00. Following the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $154,200. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.08% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: What is the Ex-Dividend Date in Investing?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.